Enovix Corporation
$745.90M- Market cap
- $728.57M
- Debt
- +$529.37M
- Cash
- −$512.04M
Capital structure 58% equity / 42% debt · EV / Revenue 23.44x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ENVX stock price at premium vs INCY $3.32 current versus $0.71 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INCY's multiple
Implied fair value · at ENVX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ENVX FY 2025 (ended Dec 28, 2025) · INCY FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 58% equity / 42% debt · EV / Revenue 23.44x
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
INCY carries the larger enterprise value at $23.73B against $745.90M; INCY trades on the lower EV / Revenue multiple (4.62x vs 23.44x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Enovix Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
INCYTE CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.95x
0.29x
Net debt / EBITDA
Leverage against operating earnings
-0.15x
-0.90x
Cash and equivalents
Liquid reserves on the balance sheet
$512.04M
$3.10B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
QuantumScape Corp
ENVX vs QS
Eos Energy Enterprises, Inc.
ENVX vs EOSE
Microvast Holdings, Inc.
ENVX vs MVST
AEHR TEST SYSTEMS
ENVX vs AEHR
AMGEN INC
ENVX vs AMGN
GILEAD SCIENCES, INC.
ENVX vs GILD
VERTEX PHARMACEUTICALS INC / MA
ENVX vs VRTX
REGENERON PHARMACEUTICALS, INC.
ENVX vs REGN
BIOGEN INC.
ENVX vs BIIB
$529.37M
$1.51B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.